Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Clinical trial NCT02157298 · COMPLETED
Trial details
- NCT number
- NCT02157298
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-01
- Primary completion
- 2015-02-01
- Enrollment
- 266
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.